The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c

Kahn, 2006, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy., N Engl J Med, 355, 2427, 10.1056/NEJMoa066224

Bolen, 2007, Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus., Ann Intern Med, 147, 386, 10.7326/0003-4819-147-6-200709180-00178

Shaw, 2005, The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin., Science, 310, 1642, 10.1126/science.1120781

Shu, 2007, Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action., J Clin Invest, 117, 1422, 10.1172/JCI30558

Cusi, 1996, Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus., J Clin Endocrinol Metab, 81, 4059

Graham, 2011, Clinical pharmacokinetics of metformin., Clin Pharmacokinet, 50, 81, 10.2165/11534750-000000000-00000

Pentikainen, 1979, Pharmacokinetics of metformin after intravenous and oral administration to man., Eur J Clin Pharmacol, 16, 195, 10.1007/BF00562061

Xia, 2007, Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells., Am J Physiol Renal Physiol, 292, F682, 10.1152/ajprenal.00302.2006

Zhou, 2007, Molecular determinants of substrate selectivity of a novel organic cation transporter (PMAT) in the SLC29 family., J Biol Chem, 282, 3188, 10.1074/jbc.M609421200

Zhou, 2007, Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine., Drug Metab Dispos, 35, 1956, 10.1124/dmd.107.015495

Koepsell, 2004, Polyspecific organic cation transporters: their functions and interactions with drugs., Trends Pharmacol Sci, 25, 375, 10.1016/j.tips.2004.05.005

Koepsell, 2004, The SLC22 drug transporter family., Pflugers Arch, 447, 666, 10.1007/s00424-003-1089-9

Muller, 2005, Drug specificity and intestinal membrane localization of human organic cation transporters (OCT)., Biochem Pharmacol, 70, 1851, 10.1016/j.bcp.2005.09.011

Koepsell, 2007, Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications., Pharm Res, 24, 1227, 10.1007/s11095-007-9254-z

Leabman, 2003, Estimating the contribution of genes and environment to variation in renal drug clearance., Pharmacogenetics, 13, 581, 10.1097/00008571-200309000-00007

Shu, 2008, Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics., Clin Pharmacol Ther, 83, 273, 10.1038/sj.clpt.6100275

Tzvetkov, 2009, The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin., Clin Pharmacol Ther, 86, 299, 10.1038/clpt.2009.92

Becker, 2009, Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus., Pharmacogenomics J, 9, 242, 10.1038/tpj.2009.15

Becker, 2009, Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study., Diabetes, 58, 745, 10.2337/db08-1028

Chen, 2009, Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin., Pharmacogenet Genomics, 19, 497, 10.1097/FPC.0b013e32832cc7e9

Song, 2008, Genetic variants of the organic cation transporter 2 influence the disposition of metformin., Clin Pharmacol Ther, 84, 559, 10.1038/clpt.2008.61

Wang, 2008, OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine., Pharmacogenet Genomics, 18, 637, 10.1097/FPC.0b013e328302cd41

Choi, 2009, Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1., Pharmacogenet Genomics, 19, 770, 10.1097/FPC.0b013e328330eeca

Kajiwara, 2009, Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity., J Hum Genet, 54, 40, 10.1038/jhg.2008.1

Ronaghi, 1998, A sequencing method based on real-time pyrophosphate., Science, 281, 363, 10.1126/science.281.5375.363

Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine., Nephron, 16, 31, 10.1159/000180580

Nies, 2009, Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver., Hepatology, 50, 1227, 10.1002/hep.23103

Cho, 2011, Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants., Clin Pharmacol Ther, 89, 416, 10.1038/clpt.2010.266

Barrett, 2005, Haploview: analysis and visualization of LD and haplotype maps., Bioinformatics, 21, 263, 10.1093/bioinformatics/bth457

Stephens, 2001, A new statistical method for haplotype reconstruction from population data., Am J Hum Genet, 68, 978, 10.1086/319501

Stephens, 2005, Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation., Am J Hum Genet, 76, 449, 10.1086/428594

Shu, 2003, Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1., Proc Natl Acad Sci USA, 100, 5902, 10.1073/pnas.0730858100

Kerb, 2002, Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences., Pharmacogenetics, 12, 591, 10.1097/00008571-200211000-00002

Leabman, 2002, Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function., Pharmacogenetics, 12, 395, 10.1097/00008571-200207000-00007

Sambol, 1996, Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus., J Clin Pharmacol, 36, 1012, 10.1177/009127009603601105

Sirtori, 1978, Disposition of metformin (N,N-dimethylbiguanide) in man., Clin Pharmacol Ther, 24, 683, 10.1002/cpt1978246683

Timmins, 2005, Steady-state pharmacokinetics of a novel extended-release metformin formulation., Clin Pharmacokinet, 44, 721, 10.2165/00003088-200544070-00004

Wang, 2002, Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin., J Pharmacol Exp Ther, 302, 510, 10.1124/jpet.102.034140

Zhou, 2009, Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study., Diabetes, 58, 1434, 10.2337/db08-0896

Zolk, 2009, Current understanding of the pharmacogenomics of metformin., Clin Pharmacol Ther, 86, 595, 10.1038/clpt.2009.144

Zhou, 2011, Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes., Nat Genet, 43, 117, 10.1038/ng.735